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Abstract We found a novel dystrophin-associated protein 
(DAP) exhibiting almost the same mobility as y-sarcoglycan on 
SDS-PAGE. This novel DAP with basic charge is separated 
from y-sarcoglycan by 2-dimensional PAGE or de-/V-glycosyla-
tion followed by SDS-PAGE. This DAP is most likely the rabbit 
homologue of "8-sarcoglycan", the y-sarcoglycan-like protein 
identified previously |Nigro et al. (1996) Hum. Mol. Genet. 5, 
1179-1186], since an internal amino acid sequence from the DAP 
matched the predicted amino acid sequence of "human 8-
sarcoglycan" within the limits of species difference and this 
DAP was recognized by anti-"5-sarcoglycan" antibody. The 
DAP was found to be contained in the sarcoglycan fraction which 
was prepared by treatment of the dystrophin-DAP complex with 
n-octyl ß-D-glucoside and crosslinked with ß- and/or y-sarcogly-
can by a chemical crosslinker, dithiobis(succinimidyl propionate). 
Therefore, we concluded that the DAP is the fourth component of 
the sarcoglycan complex. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Dystrophin is a cytoskeletal protein lining the sarcolemma 
and its loss causes Duchenne muscular dystrophy [1]. It is 
associated with a transmembranous dystroglycan complex 
which connects dystrophin with the basement membrane pro-
tein laminin [2^1] at the region (D-domain [5]) composed of 
the cysteine-rich and the first half of the C-terminal domains. 
The dystroglycan complex is composed of two dystrophin-
associated proteins (DAPs), a- (156 kDa) and ß-dystroglycans 
(43 kDa) which are post-translationally derived from a single 
gene product [4]. There is another biochemically defined com-
plex, the sarcoglycan (SG) complex, which is composed of the 
transmembranous DAPs a- (50 kDa), ß- (43 kDa) and y-SGs 
(35 kDa) [2]. The SG complex may be associated with dystro-
phin and/or the dystroglycan complex. Besides these DAPs, 
three syntrophins/Al (60 kDa), dystrobrevin/AO (60 and 90 
kDa) and 25DAP/A5 (25 kDa) have been identified to date 
[6,7]. 
We previously found that the SG complex is absent or 
greatly reduced in the skeletal muscles of patients suffering 
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from a Duchenne-like muscular dystrophy, namely, severe 
childhood autosomal-recessive muscular dystrophy 
(SCARMD), and hypothesized that SCARMD is a SG com-
plex-deficiency disease, namely, a sarcoglycanopathy [5,8]. In 
this hypothesis we assumed that the SG complex is a func-
tional unit and that, if any SG gene is defective, the complex 
would not be formed and fixed on the sarcolemma. Later, the 
cDNAs of a-, ß- and y-SGs were cloned and their gene loci 
were mapped on human chromosomes at 17q21, 4ql2 and 
13ql2, respectively [9-11]. Patients with defects in any one 
of these SG genes were identified among those suffering 
from SCARMD. It was found that not only the SG whose 
gene is defective but also the other SGs were absent in the 
skeletal muscles of the patients. Our hypothesis is supported 
by these findings. 
Recently, Nigro et al. reported the cloning of human cDNA 
encoding the protein which is highly homologous to y-SG 
(70% similarity at the amino acid level) [12]. They named 
the protein 8-SG on the basis of its homology with y-SG 
and the location of its gene on human chromosomes (5q33) 
which is the same as that of the new SCARMD (LGMD2F) 
gene determined by linkage analysis [13], although evidence 
that the protein is a DAP or an SG has not been obtained. In 
the present study, we found a novel DAP which is most likely 
"S-SG" in the purified rabbit dystrophin-DAP complex. This 
DAP was shown to be crosslinked with ß- and/or y-SGs. 
Therefore, we conclude that this novel DAP is exactly an 
SG, namely, the fourth component of the SG complex. 
2. Materials and methods 
2.1. De-N-glycosylation and crosslinking 
Dystrophin-DAP complex was prepared from rabbit skeletal muscle 
[14]. The SG complex fraction corresponding to peak 5 in Fig. 1 in [2] 
was prepared as described [2]. Dystrophin-DAP complex at 0.6 mg/ml 
was incubated with or without /V-glycosidase F (6.3 U/ml, Boehringer-
Mannheim, Indianapolis, USA) for 25 h at 37°C in the presence of 
0.1% digitonin, 0.15 M NaCl, 20 mM HEPES-NaOH (pH 7.5), 1 mM 
dithiothreitol and 5 mM o-phenanthroline. The SDS-denatured dys-
trophin-DAP complex (0.17 mg/ml) was also treated with /V-glycosi-
dase F (1.7 U/ml) for 2 h at 37°C in the presence of 0.1% SDS, 1% 
Triton X-100, 50 mM HEPES-NaOH (pH 7.5), 0.3 mM dithiothreitol 
and 5 mM o-phenanthroline. 
The SG complex fraction prepared from 50 u,g of dystrophin-DAP 
complex was dialysed against a solution of 40 mM rc-octyl ß-D-gluco-
side, 0.1 M NaCl and 20 mM HEPES-NaOH to remove dithiothreitol 
and then crosslinked with 0.4 mM dithiobis(succinimidyl propionate) 
(DSP, Pierce, Rockford, USA) according to a previously described 
method [2]. The crosslinked complex was denatured with 1% SDS 
and 1 mM /V-ethylmaleimide, and dialysed against 0.03% SDS and 
15 mM HEPES-NaOH (pH 7.5). The dialyzate was then concentrated 
to one-third its initial volume by a centrifugation evaporator and the 
concentrate was mixed with Triton X-100 to a final concentration of 
1%. The complex thus treated was separated into two parts and each 
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Fig. 1. Alignment of the N-terminal sequence of polypeptides de-
rived from the 35-kDa DAP(s) separated by SDS-PAGE of the SG 
complex fraction with the corresponding internal sequences of hu-
man "8-SG", human and rabbit y-SGs. Rabbit peptide 2 was ob-
tained together with rabbit peptide 1 whose N-terminal sequence 
was used for identification of y-SG cDNA [9]. A lowercase k means 
the lysine residue presumed, since the polypeptide was obtained 
with Acromobacter protease I (lysyl endopeptidase) ; lowercase v and 
e denote the valine and glutamic acid residues determined with 
slightly lower confidence, respectively, and * indicates that the resi-
due at that position was not determined. Bold letters denote the res-
idues which do not match between "8-SG" and y-SG. The internal 
sequences of human "8-SG", human and rabbit y-SGs were taken 
from the published sequences [9,12]. 
part was incubated with or without 7V-glycosidase F (3 U/ml) for 2 h 
at 37°C. One-fifth (for silver staining) or one-twenty-fifth (for immu-
noblotting) of each preparation was used for each electrophoresis. 
2.2. Electrophoresis and immunoblotting 
Conventional SDS-PAGE and O'Farrell-type 2-dimensional PAGE 
were performed according to [2]. Diagonal SDS-PAGE was also per-
formed as described previously [2]. A gradient gel (4.5-15%) or a 
homogeneous gel (9%) in a capillary tube were used for the first-
dimensional SDS-PAGE under non-reducing conditions. After elec-
trophoresis, each gel was pushed out of the tube and placed on top of 
a slab gel (9 or 10%). The cylindrical gel was treated with 0.1 M 
dithiothreitol and 5% 2-mercaptoethanol for 1 h at room temperature 
to reduce the disulfide bond and subjected again to SDS-PAGE. The 
proteins were stained using a 2D-Silver Stain II 'Daiichi' kit (Daiichi 
Pure Chemicals, Tokyo, Japan). The proteins electroblotted on to a 
polyvinylidene difluoride membrane (Millipore, Bedford, USA) were 
stained with an AuroDye forte kit (Amersham, Little Chalfont, UK) 
or with antibodies using an ECL detection kit. 
2.3. Antibodies 
Polyclonal antibodies, PA2, PA3b-l, and PA3a, were raised against 
the a-SG C-terminal polypeptide [2], native ß-SG [2], and the ß-dys-
troglycan intracellular polypeptide [15], respectively. Anti-"8-SG" 
antibody which is identical to anti-8-SG antibody used in [12] was 
raised against a fusion protein of glutathione 5-transferase (GST) and 
the "8-SG" fragment including most part of the extracellular domain. 
A monoclonal antibody, MA4-2, was raised against the native y-SG 
[16]. 
Fig. 2. Analysis of the dystrophin-DAP complex. The dystrophin-DAP complex which was de-JV-glycosylated or not in the presence of digito-
nin was separated by SDS-PAGE on a 4.5-15% gradient slab gel. (a) Silver staining; (b,c) staining of the proteins blotted on to a polyvinyli-
dene difluoride membrane with antibodies and colloidal gold. For comparison among the de-JV-glycosylated DAPs in the immunoblot analysis, 
a mixture of anti-a-SG antibody (PA2) with each specified antibody was used for staining in (c). Samples, 0.7 ng, 10-50 ng and 100 ng per 
lane, were used for silver staining, antibody staining and gold staining, respectively. S, de-TV-glycosylated sample; C, native sample; dys, dystro-
phin; syns, syntrophins; DG, dystroglycan; DB, dystrobrevin/AO; SG, sarcoglycan; DAPx, a novel protein; (dg), de-W-glycosylation. Abbrevia-
tions anti a-SG, anti ß-SG, anti y-SG and anti ß-DG represent the antibodies against a-SG, ß-SG, y-SG and ß-DG, respectively. 
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Fig. 3. Analysis of the dystrophin-DAP complex with anti-"8-SG" antibody. (a,b) Dystrophin-DAP complex separated by SDS-PAGE on a 
4.5-15% gradient slab gel; (c,d) dystrophin-DAP complex separated by O'Farrell-type 2-dimensional PAGE. The complex which was incubated 
in the presence of SDS with or without 7V-glycosidase F was used in these experiments. In (a,b) samples were loaded at 30 ng per lane. In (c,d) 
samples were loaded at 120 ng per gel on the acidic side. In (b), a mixture of anti-a-SG antibody with each specified antibody was used for 
comparison of the mobilities of DAPs. A faint tiny spot marked with an arrowhead in (d) seems to be DAPx, showing that anti-y-SG antibody 
very weakly crossreacts with this DAP. S, sample de-JV-glycosylated in the presence of SDS; C, native sample; anti "8-SG", anti-"8-SG" anti-
body. Other abbreviations used are the same as those in Fig. 2. 
3. Results 
3.1. N-terminal sequence of polypeptides proteolytically derived 
from the 35-kDa DAP(s) 
Previously we obtained two divergent internal amino acid 
sequences from the 35-kDa DAP(s) of the SG complex frac-
tion [9]. One of them (rabbit peptide 1 in Fig. 1) was con-
tained in the deduced amino acid sequences from the rabbit 
and human y-SG cDNAs cloned by us [9]. The other sequence 
(rabbit peptide 2), which was not published at that time, was 
similar, but different from the y-SG cDNA. The second pep-
tide, instead, matched the deduced amino acid sequence of 
human "5-SG" cloned by Nigro et al. [12], within the limits 
of species difference. This result suggests that "8-SG" is in-
cluded along with y-SG in the 35-kDa DAPs. 
3.2. De-N-glycosylation of dystrophin-DAP complex 
We examined the effect of de-Af-glycosylation on dystro-
phin-DAP complex by SDS-PAGE. As shown in the silver-
staining patterns (Fig. 2a), the electrophoretic mobilities of 
some DAPs clearly changed as a result of this treatment, 
but those of a-dystroglycan, 25DAP and the cytoskeletal 
DAPs dystrobrevin/AO and the syntrophins did not seem to 
change. We then examined the change by immunoblot analy-
sis. As shown in Fig. 2b, we observed that the electrophoretic 
mobilities of a-, ß- and y-SGs increased but that of ß-dystro-
glycan hardly changed. These results are consistent with those 
in previous reports [10,17]. However, by precisely comparing 
the relative mobilities of de-TV-glycosylated proteins using oe-
SG as an internal standard (Fig. 2c), we found that, in addi-
tion to the fact that the mobility of ß-SG became very close to 
that of y-SG, a new protein [de-N-glycosylated DAPx desig-
nated (dg)DAPx in the figure] was separated and exhibited a 
faster mobility than ß- and y-SGs. The molecular mass of this 
protein is estimated to be approx. 33 kDa. This protein could 
not be stained with the antibodies against DAPs used here. 
Therefore, we considered this DAPx to be a novel DAP 
which, without de-Af-glycosylation, could not be separated 
from other DAP (probably y-SG) by SDS-PAGE. 
3.3. Immunoblot analysis of dystrophin-DAP complex with 
anti-"8-SG" antibody 
The molecular mass of (dg)DAPx is close to 32.2 kDa 
which was estimated based on the amino acid sequence de-
duced from "8-SG" cDNA. To determine the relationship 
between DAPx and "8-SG", immunoblot analysis was carried 
out with antibody specific to "8-SG". The antiserum, which 
was raised against a fusion protein of GST and a C-terminal 
fragment of "8-SG" including the most part of the extracel-
lular domain, cross-reacted with y-SG (data not shown) as 
expected from their amino acid sequence homology [12]. After 
complete removal of the reactivities against y-SG by their 
absorption with GST-y-SG fusion protein, however, the anti-
serum (anti-"8-SG" antibody) stained a protein of almost the 
same molecular mass as y-SG in the native sample (Fig. 3a,b) 
as well as a GST-"8-SG" fusion protein [12]. In the de-N-
glycosylated sample, anti-"8-SG" antibody stained the 
(dg)DAPx we found but did not seem to stain y-SG (35 
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Fig. 4. Analysis of the crosslinked SGs. The SG complex fraction which was crosslinked with DSP and incubated with or without N-glycosi-
dase F was separated by diagonal SDS-PAGE. (a) SG complex fraction incubated without iV-glycosidase F; (c-e) SG complex fraction incu-
bated with JV-glycosidase F. (a,c) Silver staining; (d,e) staining of the proteins blotted onto a polyvinyhdene difluoride membrane with specified 
antibodies; (b) schematic figure showing the directions in two consecutive electrophoresis runs and the conditions under which they were per-
formed. Crosslinked and uncrosslmked proteins are indicated as X and un-X, respectively. Other abbreviations used are the same as those in 
Figs. 2 and 3. 
kDa). Furthermore, for the native sample separated by 2-di-
mensional PAGE, we found in the immunoblot analysis that 
it stained a basic protein but did not stain the acidic DAP y-
SG (Fig. 3c,d). The basic protein is considered to be coinci-
dent with spot 12 of Fig. 2 in [18]. We also found that a 
monoclonal antibody against y-SG which was useful for clon-
ing the cDNA [9] faintly stains the basic protein (Fig. 3d) and 
a GST-"8-SG" fusion protein (data not shown). These results 
show that DAPx is a novel DAP which is immunochemically 
related to "8-SG" as well as y-SG and a basic protein with 
almost the same molecular mass as y-SG in the native state. 
3.4. Chemical crosslinking of the SG complex fraction by 
DSP 
We previously showed that DAPs can be separated into a 
dystroglycan complex, an SG complex and other components 
by treatment of the dystrophin-DAP complex with n-octyl ß-
D-glucoside followed by gel filtration [2,5]. It was shown by 
de-./V-glycosylation of each fraction that DAPx is recovered in 
the SG complex fraction (data not shown). This observation 
suggests that DAPx is another component of the SG complex. 
If this is the case, it should be possible to crosslink DAPx with 
other known SGs by a chemical crosslinker. The SG complex 
fraction was thus treated with a chemical crosslinker, DSP, 
which is cleavable by reduction, and then de-N-glycosylated 
with 7V-glycosidase F. The crosslinked products were analysed 
by diagonal SDS-PAGE, which was previously used to detect 
crosslinking among DAPs [2]. After separation by this tech-
nique, the uncrosslinked proteins, if any, appear along a diag-
onal line on the gel, since their mobilities along the second 
dimension are not modified by reduction. Crosslinked pro-
teins, however, appear below this diagonal, since they run 
faster along the second dimension when dissociated by reduc-
tion. The results for the native sample showing formation of a 
product composed of ß- and y-SGs (Fig. 4a) were essentially 
the same as those previously obtained for the SG complex 
fraction [2]. Therefore, ß- and y-SGs exist in a complex. As 
described previously [2], the association of a-SG with the ß-
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and y-SGs was not detected by crosslinking but was demon-
strated by immunoprecipitation. In the de-N-glycosylated 
sample (Fig. 4c), we detected a main crosslinked product com-
posed of two protein spots. These are similar but distinct from 
those obtained for the native sample. Immunoblot analysis 
(Fig. 4d,e) showed that the upper and lower protein spots 
are identical to de-N-glycosylated y-SG and DAPx, respec-
tively. In this experiment, ß-SG was no longer detected with 
its specific antibody, probably because the epitope was modi-
fied with DSP. However, considering that ß-SG is electro-
phoresed very close to y-SG after de-JV-glycosylation in the 
conventional SDS-PAGE (Fig. 2c), ß-SG should be included 
in the upper protein spot together with y-SG. These results 
demonstrate that DAPx is crosslinked with ß- and/or y-SGs 
and thus exists in a complex with these SGs. Therefore, we 
conclude that DAPx is a novel SG, the fourth component of 
SG complex. 
4. Discussion 
Here we suggest that a novel DAP included along with y-
SG in the 35-kDa DAPs of the SG complex fraction is the 
rabbit homologue of "8-SG". We showed that an internal 
amino acid sequence, which was obtained from the 35-kDa 
DAPs separated by SDS-PAGE of the SG complex fraction 
[9], matches that of human "S-SG" cloned by Nigro et al. [12] 
within the limits of species difference. We assume this because 
the amino acid changes are less than 5% by cloning of "5-SG" 
cDNA from several other mammals (Nigro et al., unpublished 
results). We previously found a protein (spot 12 of Fig. 2 in 
[18]) with the same molecular size as but with a basic charge 
different from y-SG by two-dimensional PAGE of dystrophin-
DAP complex. Furthermore, in the present study, we found a 
novel DAP [(dg)DAPx] by de-A^-glycosylation of dystrophin-
DAP complex followed by SDS-PAGE. Anti-"5-SG" anti-
body reacted with this DAP and, in the native complex, re-
acted with a 35-kDa basic DAP (DAPx) which is assumed to 
be spot 12. The molecular size and charge of DAPx are con-
sistent with those calculated based on the amino acid sequence 
deduced from the "8-SG" cDNA. Therefore, we conclude that 
DAPx is a novel DAP suggestive of "8-SG". DAPx was also 
shown to be recovered in the SG complex fraction when the 
dystrophin-DAP complex was treated with w-octyl ß-D-gluco-
side and separated by gel filtration, and crosslinked with ß-
and/or y-SGs. Therefore, we further conclude that DAPx is 
exactly an SG, namely, 8-SG, which means the fourth com-
ponent of the SG complex. 
When the SG complex fraction was crosslinked with DSP in 
a previous study [2], the molecular mass of the product was 
found to be approx. 110 kDa. Since this should be the sum of 
the masses of 35 kDa for y-SG and 43 kDa for ß-SG, we had 
assumed their molar ratio in the product to be either 1:2 (113 
kDa) or 2:1 (121 kDa). However, considering the new finding 
that 35-kDa 8-SG is contained in the crosslinked product 
along with ß- and y-SGs, it would be more reasonable to 
assume that the product is formed by ß-, y- and 8-SGs in 
an equimolar ratio (113 kDa). This suggests that one 43-
kDa and two 35-kDa SGs are present in equimolar amounts 
in the SG complex or dystrophin-DAP complex. In this con-
text, we take note of Beckmann's proposal on the basis of 
genetic analysis that the molar ratio of SGs in the complex 
should be unity [19]. Considering that there exist two 35-kDa 
SGs (y and 8), it is assumed that rabbit peptide 2 in Fig. 1 was 
derived from 8-SG. 
"8-SG" is a protein homologous to y-SG (55% identity and 
70% similarity at the amino acid level) [12]. Its mRNA is 
expressed in skeletal, cardiac and smooth muscles and the 
protein product is immunohistochemically found on the sur-
face membrane of skeletal muscle like dystrophin and DAPs. 
The gene encoding "8-SG" is located on the human chromo-
some at 5q33 [12], which coincides with a new gene locus 
mapped by linkage analysis for Brazilian SCARMD families 
[13]. Analysis of DNA from the patients in these families 
revealed a homozygous deletion of a single cytidine in the 
"8-SG" gene producing a premature stop codon [20]. In biop-
sied muscles of the patients, all SGs including "8-SG" were 
shown to be absent. Based on our sarcoglycanopathy hypoth-
esis that the gene defect of every SG causes SCARMD [5,8], 
all these facts strongly suggest that "8-SG" is an SG and this 
protein should be found in the SG complex. In the present 
study, we biochemically found 8-SG, whose natures are con-
sistent with "8-SG". Therefore, we are of the opinion that "8-
SG" is 8-SG. 
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